Novo Nordisk's shares fell 19% at the opening bell in Copenhagen after the company issued disappointing guidance for the upcoming year, raising concerns among investors about its future performance.

Novo Nordisk, the Danish weight-loss drugmaker, has announced that its U.S. sales are projected to decline by as much as 13% this year due to increasing competition in the diabetes and obesity markets. This news has led to a significant drop in the company's shares.

Home births are increasingly being chosen by women who express skepticism towards the medical establishment, influenced by romanticized narratives shared on social media. This trend reflects a growing desire for autonomy in childbirth and a shift in how women perceive traditional medical practices.

About 2.1 million people in the U.S. are expected to be diagnosed with cancer this year, highlighting the significant impact of cancer on public health. Research indicates that individual behaviors can influence cancer risk, emphasizing the importance of awareness and preventive measures.

AstraZeneca's initial application for a lupus injection has been rejected by the FDA, prompting the company to collaborate with the U.S. regulator on an updated submission, with a decision anticipated in the first half of 2026.

AstraZeneca has entered into a multibillion-dollar agreement with China's CSPC Pharmaceuticals to acquire rights to a portfolio of early-stage experimental drugs targeting obesity and diabetes, marking the largest deal of its kind in terms of potential value.

At the start of every year, pharmaceutical companies typically raise prices for their medicines. However, this year marks a shift as some popular treatments have seen price reductions, influenced by changes in federal government policies.